BC
TARS icon

Bayforest Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Bayforest Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
1,641
+938
+133% +$59.9K 0.1% 409
2026
Q1 		$49.3K Buy
+703
New +$49.1K 0.06% 561

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bayforest Capital's TARS Position: Q2 2026 in Review

Bayforest Capital increased its Tarsus Pharmaceuticals (TARS) stake by 133% in Q2 2026, buying an estimated $59.9K and bringing the position to 1,641 shares worth $103K. The position accounts for 0.1% of the portfolio, ranked #409.

Bayforest Capital first reported a position in TARS in Q1 2026 and has held it in 2 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Bayforest Capital held 1,641 shares of Tarsus Pharmaceuticals worth $103K as of Q2 2026.
  • Bayforest Capital bought 938 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $59.9K.
  • Tarsus Pharmaceuticals made up 0.1% of Bayforest Capital's portfolio in Q2 2026, its #409 holding.
  • Bayforest Capital first reported a position in Tarsus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.